New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals
New Analysis on Icosapent Ethyl: A post hoc analysis from the REDUCE-IT study shows that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use, reinforcing its role in comprehensive cardiovascular risk management.
FDA Update on Fibrates: The FDA has updated labeling for fibrates, indicating they do not provide cardiovascular benefits when used with statins, highlighting the need for more effective therapies to address residual cardiovascular risk.
Commitment to Cardiovascular Care: Amarin Corporation emphasizes its dedication to advancing cardiovascular care and raising awareness about the importance of FDA-approved therapies like VASCEPA (icosapent ethyl) for patients with elevated triglycerides.
Efficacy and Safety Profile: The analysis indicates that icosapent ethyl offers cardiovascular protection beyond standard therapies without additional safety concerns, addressing a critical evidence gap in cardiovascular treatment.
Trade with 70% Backtested Accuracy
Analyst Views on AMRN
About AMRN
About the author
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.
Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.
Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.
Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.
